IP Library Granted Patent US 8,535,696
Granted Patent B2
US 8,535,696 · App. 13/405,203 · Granted Sep 17, 2013

Treating eczema and/or psoriasis

Inventors: Timothy David Meakin (Auckland, NC); Dianne Cadwallader (Auckland, NC); Craig Leonard Heatley (Auckland, NZ)
Assignee: Lypanosys Pte Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,535,696
App. No.
13/405,203
Granted
Sep 17, 2013
Kind
B2
Abstract

The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.

Claims (9)

1. A method of treatment of eczema in a mammal, comprising administering or having self-administered to said mammal an effective amount of a medicament consisting of cetyl myristate and one or both of an excipient and a diluent, wherein said administration is oral administration, and wherein said mammal is suffering from eczema.

2. The method of claim 1 , wherein said mammal is a human being suffering from eczema.

3. A method of treatment of eczema in a mammal, comprising administering or having self-administered to said mammal an effective amount of a medicament for relief of a symptom of eczema, wherein said medicament consists of cetyl myristate and one or both of an excipient and a diluent, and wherein said mammal is suffering from eczema.

4. The method of claim 3 , wherein said administering is effective in reducing itching associated with said eczema.

5. The method of claim 3 , wherein said administering is effective in healing eczema lesions.

6. The method of claim 3 , wherein said administering is effective in returning skin to a smooth unblemished appearance.

7. The method of claim 3 , wherein said mammal is using a steroid at the onset of said administering, and said method further comprises reducing use of the steroid by said mammal.

8. The method of claim 3 , wherein said mammal is a human being suffering from eczema.

9. The method of claim 3 , wherein said cetyl myristate is present in a dosage unit containing between 5 to 400 mg cetyl myristate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: MEAKIN, TIMOTHY DAVID; HEATLEY, CRAIG LEONARD; CADWALLADER, DIANNE
To: MERACOL CORPORATION LIMITED
Reel/Frame 028247/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: MERACOL CORPORATION LIMITED
To: MERACOL INVESTMENTS LIMITED
Reel/Frame 028247/0513 →
CHANGE OF NAME Recorded May 22, 2012
From: MERACOL INVESTMENTS LIMITED
To: LYPANOSYS LIMITED
Reel/Frame 028247/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: LYPANOSYS LIMITED
To: LYPANOSYS PTE LIMITED
Reel/Frame 028247/0579 →
Priority Claims (2)
NZ 504525 · May 12, 2000 · national
NZ 507228 · Sep 28, 2000 · national
Continuity (3)
Continuation 11056008 · Feb 14, 2005
Division 10275269
Related Publication 20120157525A1 · Jun 21, 2012